Why the study?
Does continuous intravenous infusion of Adriamycin improve objective response and reduce toxicity in patients with metastatic breast cancer?
Population
27 patients with metastatic breast cancer previously treated with non-Adriamycin containing chemotherapy.
Design
Case_series
Authors
Loading...
May support 96-hour Adriamycin infusion to limit cardiac toxicity in metastatic breast cancer; hypothesis-generating and requires randomized confirmation.
Does continuous intravenous infusion of Adriamycin improve objective response and reduce toxicity in patients with metastatic breast cancer?
Continuous 96-hour intravenous infusion of Adriamycin in metastatic breast cancer patients yields objective responses while reducing cardiac toxicity and nausea/vomiting.
Legha et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: